You are here: Industry Insights > trial

News List

AbbVie’s Elagolix Dazzles in Phase III Trial biospace
March 14, 2018
AbbVie and Neurocrine Biosciences, Inc. announced that its Phase III ELARIS UF-II trial of elagolix for uterine fibroids met its primary endpoint.
AZ announces results delay for key lung cancer trial pharmatimes
March 13, 2018
AstraZeneca and research arm MedImmune have announced a longer wait for survival data from a closely-watched trial testing Imfinzi in advanced lung cancer.
Enrollment Completed in Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer biospace
March 13, 2018
Eleven Biotherapeutics, Inc.today announced that the company has completed enrollment in the VISTA Phase 3 registration trial of Vicinium™ in patients with non-muscle invasive bladder cancer
Unum Therapeutics Looks to File IPO, Reveals Patient Deaths in Early Clinical Trial biospace
March 06, 2018
After a flurry of c-suite and board appointments, Unum Therapeutics is looking to take the company public.
Zhejiang Medicine Terminates Phase III Oncology Trial biospace
December 25, 2017
Zhejiang Medicine Co. Ltd. has terminated its Phase III oncology trial for oral forms of prochloridine mesylate to treat acute myeloid leukemia due to a lack of efficacy.
The Lancet Publishes Twelve-Month Results for DESSOLVE III Highlighting MiStent® Performance in All- prnasia
December 08, 2017
Micell Technologies, Inc. announced that The Lancet has published data from the DESSOLVE III clinical trial.
Forty Seven raises another $75M to expand I-O trial slate fiercebiotech
October 19, 2017
New backer Wellington Management led the round with the support of Clarus, Lightspeed Venture Partners, Sutter Hill Ventures and GV, the four VCs that drove Forty Seven to its $75 million series A 20 months ago.
Spyryx Biosciences Announces First Patient Enrolled in SPX-101 Trial americanpharmaceuticacreview
October 19, 2017
HOPE-1 is a 28-day study using an adaptive design testing two doses of SPX-101 against placebo in each of two serial cohorts of patients.
New trial ordered, all previous judgements vacated in Sanofi, Amgen Praluent® (alirocumab) patent ca pharmaasia
October 18, 2017
Sanofi and Regeneron will continue all regular Praluent® (alirocumab) sales and operations in the U.S. as usual in the meantime.
Bonesupport enrols first patient in injectable bone graft substitute trial europeanpharmaceuticalreview
May 26, 2017
Bonesupport, the Scandinavian medical technology company, has enrolled their first patient at the University of Texas Health Science Center at San Antonio into the company’s pivotal Investigational Device Exemption (IDE) trial.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page